HEALTH regulator said that the available data does not establish a link between a popular class of diabetes and obesity drugs, including Novo Nordisk's Wegovy, and suicidal thoughts.
The Medicines and Healthcare products Regulatory Agency (MHRA) began a review of safety data for the class of drugs, known as GLP-1 receptor agonists, more than a year ago after some patients reported suicidal or self-harming thoughts.
"We conclude that the available data does not support a causal association between GLP-1 receptor agonists and suicide, suicidal ideation, self-injury and depression, and therefore no updates to the product information is warranted at this time," it said in a statement.
The UK review began weeks after similar action by the European Union. It included Wegovy and another Novo Nordisk drug, Ozempic, which contains the active ingredient semaglutide and is approved to treat Type 2 diabetes.
The EU drug regulator said in April that its own review had found no evidence that the class of medicines are linked to suicidal thoughts.
The US Food and Drug Administration said in January that its preliminary review had not found evidence that GLP-1 drugs were linked to suicidal thoughts, but that it will continue to study the issue.
(Reuters)
Mythri Movie Makers eye massive collaboration with SRK for their next big ventureGetty Images 
Shah Rukh Khan may become India’s highest-paid actor with this upcoming filmGetty Images 
Pan-India film with ₹1000 crore budget reportedly being planned with Shah Rukh KhanGetty Images 
He discontinued taking rapamycin after research suggested it could accelerate ageingNetflix